266 related articles for article (PubMed ID: 22480308)
1. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
Carbone M; Duty S; Rattray M
BMC Neurosci; 2012 Apr; 13():38. PubMed ID: 22480308
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Sleeman IJ; Boshoff EL; Duty S
Neuropharmacology; 2012 Dec; 63(7):1268-77. PubMed ID: 22971544
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
4. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
5. Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity.
Saura J; Parés M; Bové J; Pezzi S; Alberch J; Marin C; Tolosa E; Martí MJ
J Neurochem; 2003 May; 85(3):651-61. PubMed ID: 12694391
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
Boshoff EL; Fletcher EJR; Duty S
Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
[TBL] [Abstract][Full Text] [Related]
7. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
8. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
[TBL] [Abstract][Full Text] [Related]
9. Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease.
Anastasía A; Torre L; de Erausquin GA; Mascó DH
J Neurochem; 2009 May; 109(3):755-65. PubMed ID: 19245661
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective activity of peripherally administered liver growth factor in a rat model of Parkinson's disease.
Gonzalo-Gobernado R; Calatrava-Ferreras L; Reimers D; Herranz AS; Rodríguez-Serrano M; Miranda C; Jiménez-Escrig A; Díaz-Gil JJ; Bazán E
PLoS One; 2013; 8(7):e67771. PubMed ID: 23861803
[TBL] [Abstract][Full Text] [Related]
11. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
12. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
13. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
[TBL] [Abstract][Full Text] [Related]
14. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
15. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
Oiwa Y; Yoshimura R; Nakai K; Itakura T
Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH
Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat.
Barnéoud P; Mazadier M; Miquet JM; Parmentier S; Dubédat P; Doble A; Boireau A
Neuroscience; 1996 Oct; 74(4):971-83. PubMed ID: 8895866
[TBL] [Abstract][Full Text] [Related]
18. Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice.
Douhou A; Debeir T; Murer MG; Do L; Dufour N; Blanchard V; Moussaoui S; Bohme GA; Agid Y; Raisman-Vozari R
Exp Neurol; 2002 Jul; 176(1):247-53. PubMed ID: 12093102
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
20. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy).
Scherfler C; Sather T; Diguet E; Stefanova N; Puschban Z; Tison F; Poewe W; Wenning GK
J Neural Transm (Vienna); 2005 Aug; 112(8):1025-33. PubMed ID: 15583958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
